Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > China Daily Article

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Nov 06, 2024 10:06pm

68 Views

Post# 36300174

RE:RE:RE:RE:RE:RE:China Daily Article

I think that was a good post, but not great.

what you may be missing is no one plunks down $2B without a hard look at the data.. to see if it supports an FDA approval.

oXiris data is one thing, but PMX data is another. Sepsis is a hard nut to crack.

If they have had a look ( it is somewhat open label after all) , IMO it's more likely they await top line results, with one finger on the trigger.

BTW $2B USD is darn close to $7 /share* ... so I'll give you partial marks. But next time, bring it home in terms that all here can understand, and show your rough work for additional part marks.

MM

* 2B /400M X 1.40

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant